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Abstract
Most pathological pseudoexon inclusion events originate from single activating mutations, suggesting that many intronic
sequences are on the verge of becoming exons. However, the precise mechanisms controlling pseudoexon definition are
still largely unexplored. Here, we investigated the cis-acting elements and trans-acting regulatory factors contributing to the
regulation of a previously described fibrinogen gamma-chain (FGG) pseudoexon, which is activated by a deep-intronic
mutation (IVS6-320A.T). This pseudoexon contains several G-run elements, which may be bound by heterogeneous
nuclear ribonucleoproteins (hnRNPs) F and H. To explore the effect of these proteins on FGG pseudoexon inclusion, both
silencing and overexpression experiments were performed in eukaryotic cells. While hnRNP H did not significantly affect
pseudoexon splicing, hnRNP F promoted pseudoexon inclusion, indicating that these two proteins have only partially
redundant functions. To verify the binding of hnRNP F and the possible involvement of other trans-acting splicing
modulators, pulldown experiments were performed on the region of the pseudoexon characterized by both a G-run and
enrichment for exonic splicing enhancers. This 25-bp-long region strongly binds hnRNP F/H and weakly interacts with
Serine/Arginine-rich protein 40, which however was demonstrated to be dispensable for FGG pseudoexon inclusion in
overexpression experiments. Deletion analysis, besides confirming the splicing-promoting role of the G-run within this 25-
bp region, demonstrated that two additional hnRNP F binding sites might instead function as silencer elements. Taken
together, our results indicate a major role of hnRNP F in regulating FGG pseudoexon inclusion, and strengthen the notion
that G-runs may function either as splicing enhancers or silencers of the same exon.
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Introduction
Splice-site selection in higher eukaryotes depends on multiple
parameters such as splice-site strength, presence or absence of
activating and inhibitory regulatory elements, RNA secondary
structure, and gene architecture [1]. The relative contribution of
each of these components controls how efficiently splice sites are
recognized and flanking introns are removed. In particular, every
exon has its specific set of identity elements that permit its
recognition by the spliceosome, a ‘‘splicing code’’ that precisely
defines the overall binding affinity for the splicing machinery [2,3].
While the first layer of this code, namely the consensus splice sites,
is relatively easy to identify, the additional layers are composed of
highly degenerated signals that act in a complex combinatorial
way and are much more difficult to decipher. Indeed, an array of
diverse intronic and exonic splicing enhancers (ISEs and ESEs)
and silencers (ESSs and ISSs) serve as binding sites for specific
trans-acting regulatory factors to the pre-mRNA, and are thus
required either to direct the splicing machinery to the appropriate
sites or to inhibit the use of potential cryptic splice sites. ESEs, in
particular, appear to be widespread, and might be present in most,
if not all, exons, including constitutive ones. The best character-
ized ESEs promote splicing by interacting with members of the
serine/arginine-rich (SR) protein family [4]. ESE motifs are quite
degenerated and often overlapping, making them difficult to
predict on the basis of the nucleotide sequence alone. For instance,
analysis of SR-protein binding motifs showed that the major
family members recognize fairly degenerated consensus sequences,
varying from 5 to 7 nucleotides with a high purine content [5].
Silencing elements are less well characterized than ESEs, and
their mechanisms of action are still not fully understood. The
genetic context seems to be extremely important in determining
the effect of both ESSs and ISSs. A well-established regulatory
motif consisting of a stretch of three or more guanine nucleotides,
the so called ‘‘G-run’’ element, may function both as an ESS and
as an ISE, depending on its position. Indeed, it can cause exon
skipping when placed within an exon, but it can also promote exon
inclusion when located downstream of a weak 59 splice site [6].
Both ESSs and ISSs work by interacting with negative regulators,
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which often belong to the heterogeneous nuclear ribonucleopro-
tein (hnRNP) family. In particular, the hnRNP I protein (also
known as polypyrimidine-tract-binding protein, PTB) and proteins
of the hnRNP A/B and hnRNP H families are among the best-
characterized mediators of silencing [4].
Despite the efforts to classify general splicing regulatory
sequences and their binding factors, exceptions are not un-
common: classical SR proteins are known to be involved in
splicing repression in few cases [7], whereas some well-character-
ized hnRNP proteins may also act as splicing enhancers [8,9].
Therefore, experimental studies are required to clarify the role
played by even well-known splicing factors in each specific gene
context.
Deciphering the splicing code is becoming increasingly impor-
tant for the characterization of pathogenic mechanisms leading to
human disease, as up to 60% of disease-causing mutations are
found to affect splicing [10,11]. In general, changes in splicing cis-
regulatory elements can lead to exon skipping, intron retention,
creation of ectopic splice sites, or activation of cryptic ones
[12,13,14]. Another important pathological outcome of splicing
mutations, which has been long overlooked, is the activation of
pseudoexons. Despite the abundance of potential pseudoexons
(50–200 nt-long intronic sequences with apparently viable splice
sites at either end), their inclusion during normal pre-mRNA
processing seems rare, although it has been described to occur as
a regulatory mechanism for the expression of specific genes [15].
However, the actual frequency of pseudoexon activation might be
underestimated due to nonsense-mediated-mRNA degradation of
transcripts carrying out-of-frame pseudoexons. Most mutation-
induced pseudoexon inclusion events originate from a single
activating mutation, suggesting that many intronic sequences
might be poised on the brink of becoming exons [16]. These
mutations generally involve the creation of de novo functional donor
or acceptor splice sites within an intronic sequence, followed by
the subsequent selection of nearby ‘‘opportunistic’’ acceptor or
donor sites. Alternatively, other frequent mechanisms leading to
pseudoexon activation involve the creation of enhancer or loss of
silencer splicing regulatory elements. Conversely, the trans-acting
factors involved in pseudoexon inclusion are less known, although
hnRNP proteins seem to have an important modifier role [16].
We previously described a deep-intronic homozygous mutation
(IVS6-320A.T) that causes the inclusion of a 75-bp pseudoexon
between exons 6 and 7 of the fibrinogen gamma-chain gene (FGG)
transcript in a patient affected by congenital afibrinogenemia [17].
This mutation reinforces a pre-existing cryptic donor splice site by
extending its complementarity to U1snRNA, eventually resulting
in the activation of a pseudoexon. We also suggested that, apart
from the cryptic splice-site activation, the modulation of normally
silent regulatory elements could also play a role in this mutation-
induced pseudoexon inclusion [17]. In the present work, we
address this issue by functionally dissecting both the cis-acting
elements and the trans-acting regulatory factors that contribute to
the regulation of this pseudoexon insertion event.
Results
A previous work from our group demonstrated that a single
nucleotide substitution within intron 6 of the FGG gene (IVS6-
320A.T) results in the inclusion of a disease-causing pseudoexon
in nearly the totality of mature transcripts (Figure 1) [17]. This
nucleotide substitution produces an extended complementarity to
U1snRNA at a cryptic donor splice site. However, the exiguity of
residual wild-type splicing, as well as the existence in other FGG
exons (i.e. exons 3 and 9) of physiologic donor splice sites with
sequence similar to the cryptic one -which is totally neglected by
the splicing machinery in the wild-type context- suggested the
existence of splicing regulatory mechanisms modulating the
inclusion of this pseudoexon (Figure S1A). This prompted us to
investigate in more detail the in-cis and in-trans elements involved
in this pseudoexon activation/suppression.
hnRNP F Regulates Pseudoexon Inclusion in the FGG
mRNA
As a first step in the study of regulatory elements controlling
pseudoexon inclusion, we analyzed the 75-bp pseudoexon
sequence and noticed the presence of three G-runs motifs (named
G1, G2, and G3): two are located at the 59 of the pseudoexon
(positions 21 to +4 and +13/15), the third towards the 39 end
(position 60–62) (Figure 1). As hnRNP H and F are known to bind
G-runs, acting either as splicing-enhancer or splicing-inhibitory
factors depending on gene and cellular context [8,18,19], we
explored their effect on FGG pseudoexon inclusion by performing
siRNA-mediated silencing of the two proteins (Figure 2A). The
pT-FGG-IVS6-320A.T minigene (containing the mutant IVS6-
320A.T FGG genomic region spanning 1,858 bp from intron 4 to
intron 7, cloned into the pTargeT vector) [17] was thus co-
transfected into HeLa cells (not expressing fibrinogen) with
siRNAs against hnRNP F or hnRNP H. The efficacy of protein
knockdowns was verified and quantitated by Western blotting
(Figure 2A, left and central panels). Interestingly, real-time RT-
PCRs showed that knockdown of hnRNP H results in a non-
significant increase of pseudoexon inclusion, whereas hnRNP F
depletion significantly represses pseudoexon recognition
(Figure 2A, right panel). A similar result was found after double
knockdown of hnRNP F and H (data not shown), suggesting
a prominent role of hnRNP F in the modulation of FGG
pseudoexon splicing. The lack of response to hnRNP H might
raise the question whether a sufficient level of knockdown of this
protein was obtained. However, silencing of hnRNP H was
performed using exactly the same protocol and reaching the same
level of silencing (85%) that we previously showed to determine the
activation of a cryptic acceptor splice site in the thrombopoietin
gene [20].
In complementary experiments, the overexpression of hnRNP F
resulted in a further decrease of the wild-type residual transcript,
from about 5% to about 1% of the total FGG transcripts, thus
confirming the role of this factor in promoting pseudoexon
inclusion (Figure 2B). In this case, to have a more accurate
measure of the relative amount of the two splicing variants,
a fluorescent RT-PCR approach was used (see Materials and
Methods).
A 25-bp Region Binds hnRNP F and is Important for
Pseudoexon Inclusion
Besides G-runs, additional regulatory elements modulating
pseudoexon inclusion were predicted using the ESEfinder software
[21,22]. The program predicted multiple binding sites for SF2/
ASF, SC35, SRp40, and SRp55 proteins. The higher density of
high-score motifs (score .3) was found in a 25-bp region
comprised between nucleotides 7 and 27 of the pseudoexon
(Figure 3A), this region also contains one of the three G-run motifs
that may bind hnRNP F. To identify which trans-acting factors can
bind this ESE-enriched 25-bp region, an affinity pulldown
protocol was used. Both the wild-type and a scrambled (negative
control) 25-bp sequence (Figure 3B), were covalently coupled to
adipic acid dehydrazide beads and incubated with HeLa nuclear
extracts. As shown in Figure 3B (left panel), Western blotting with
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antibodies against the principal hnRNPs evidenced signals for all
four tested proteins (hnRNP H, F, A1, and A2). However,
comparison with results obtained using a scrambled or an
unrelated oligoribonucleotide revealed that the only protein
exclusively binding the 25-bp target sequence was hnRNP F.
Moreover, the binding efficiency of hnRNP H to the 25-bp probe
was much higher than that of the permutated sequence. The same
experiment performed immunodecorating with antibodies against
SR proteins evidenced a weak binding of SRp40 to the 25-bp
sequence (Figure 3B, right panel), supporting the ESEfinder
prediction for this protein. Finally, probing with additional
antibodies (i.e. anti PTB, hnRNP C) ruled out the binding of
additional common hnRNP factors to this sequence (data not
shown).
The relevance of the 25-bp region in promoting pseudoexon
inclusion was experimentally verified by deleting this sequence in
the pT-FGG-IVS6-320A.T plasmid. Transient transfection of the
25-bp-deleted construct (pT-FGG-M-del25) in HeLa cells resulted
in a change in pseudoexon inclusion from 96% to 44%, as
quantified by fluorescent RT-PCR (Figure 4A). The marked
reduction in pseudoexon inclusion confirmed that the deleted
nucleotides are necessary to reach full efficiency in pseudoexon
recognition. Similar results were obtained by qRT-PCR analysis
(see Figure S2).
To confirm that hnRNP F acts by interacting with the 25-bp
region, hnRNP F silencing was performed in cells expressing the
pT-FGG-M-del25 plasmid. In contrast with what observed in the
presence of the whole pseudoexon sequence (see Figure 2A),
silencing of hnRNP F in the absence of the 25-bp region
significantly promoted pseudoexon inclusion (Figure 4B). This
result suggests that: 1) the role of hnRNP F in enhancing
pseudoexon recognition is strictly dependent on the presence of
the 25-bp region; 2) the two G-run motifs located outside this
region may act as ESSs.
Since the predicted hnRNP F binding site within the 25-bp
region is partially overlapped to a SRp40 binding site (Figure 3A)
and that indeed a weak binding of SRp40 was evidenced by
pulldown experiments (Figure 3B), we attempted to modulate
SRp40 level in HeLa cells. While we could not reach a sufficient
level of SRp40 silencing, overexpression experiments showed that,
at least in our experimental conditions/system, the percentage of
pseudoexon inclusion is insensitive to SRp40 upregulation (Figure
S3).
Different G-run Elements Exhibit Opposite Effects in
Regulating Pseudoexon Inclusion
To further dissect the functional elements within the splicing-
promoting 25-bp region, as well as to map all hnRNP F binding
sites within the pseudoexon sequence at a higher resolution, we
decided to test the effect of the single (G1 and G2) and combined
(G1+G2, G1+G3, G2+G3, and G1+G2+G3) deletion of the three
different G-runs in the pT-FGG-IVS6-320A.T plasmid. More-
over, as pseudoexon regulation might depend on the cellular
context, transient transfections of the mutant constructs were
performed also in human hepatoma HepG2 cells, which
endogenously express fibrinogen and therefore represent a more
physiological model system than HeLa. Experiments in HepG2
showed no physiological expression of transcripts including the
FGG pseudoexon (data not shown), and a higher level of FGG wild-
type splicing (23%) in the presence of the IVS6-320A.T
mutation, thus allowing a more accurate analysis of the effects of
the different deletion constructs (Figure 5).
In HepG2, the expression of the G2-deleted construct (pT-FGG-
M-delG2), lacking the only G-run element located within the 25-
bp region, resulted in a significant reduction in pseudoexon
inclusion (from 77% to 68%) (Figure 5), confirming our hypothesis
that this hnRNP binding site functions as an ESE. Surprisingly, the
ablation of G2 had no effect on splicing in HeLa cells, indicating
a certain degree of cell type-specific responsiveness of this element.
This discrepancy might be due either to differences in the basal
level of expression of hnRNP F between the two analyzed cell
lines, or to an additional trans-acting factor only present in
HepG2. The first possibility was explored by real-time RT-PCR
Figure 1. Schematic representation of the 75-bp FGG pseudoexon activated by the IVS6-320A.T mutation. (top) The fibrinogen
cluster; boxes and lines represent exons and intronic/intergenic regions, respectively (only exons are drawn to scale); the two parallel slanted lines
indicate breaks in the scale. (middle) The FGG minigene (M) cloned in pTargeT vector; the star marks the IVS6-320A.T mutation. (bottom) The
complete 75-bp-long pseudoexon sequence and flaking splice sites; nucleotides belonging to the pseudoexon are in capital letters; the strength of
pseudoexon splice sites, calculated by using the NNSPLICE 0.9 (http://www.fruitfly.org/seq_tools/splice.html) and the Netgene2 (http://www.cbs.dtu.
dk/services/NetGene2/) software is reported below the corresponding sequence; G-stretches are shaded in gray.
doi:10.1371/journal.pone.0059333.g001
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and Western blot assays, showing significantly lower levels of both
endogenous hnRNP F mRNA and protein in HepG2 compared to
HeLa cells (Figure S4).
Contrary to what was observed for delG2 mutants, all single or
combined deletions of G-runs outside the 25-bp region resulted in
a marked increase of pseudoexon splicing in both cell types,
suggesting that G1 and G3 normally act as repressor elements
(Figure 5).
As the deletion of the G2 element alone does not completely
recapitulate the effect of the ablation of the entire 25-bp region,
and considering that hnRNP F has three RNA-recognizing motifs
arrayed in the same spacing that can bind to extended purine-rich
elements [23], we produced an additional deleted construct (pT-
FGG-M-del8) lacking the very last 8-bp purine-rich sequence of the
25-bp region. This mutant was transfected in both HeLa and
HepG2 cells again showing a cell-type specific response (Figure 5).
In particular, in HepG2 cells the ablation of the 8-bp element led
to a significantly lower inclusion of the pseudoexon (from 77% to
51% of total FGG transcripts).
Taken together, these results demonstrate that G-runs with
opposite functions contribute in determining the levels of
pseudoexon inclusion in FGG transcript, only in the presence of
the IVS6-320A.T mutation.
Discussion
Detailed knowledge on the structure of most vertebrate genes
has highlighted the presence of a large number of pseudoexon
sequences that are physiologically silenced by intrinsically de-
fective splice sites [24], by the presence of silencer elements
[25,26,27], or by the formation of inhibiting RNA secondary
structures [28]. Even though pseudoexons are expected to be low
in ESEs, the high degeneration of splicing enhancer motifs and
their relative abundance also within introns [5] suggest that
pseudoexons probably contain also a number of enhancer motifs,
Figure 2. Effect of hnRNP H and F modulation on the regulation of FGG pseudoexon splicing. (A) Knockdown of hnRNP H and F. Western
blot (left) and corresponding densitometric analysis (middle) demonstrating the actual silencing of hnRNP H and F proteins in RNAi experiments.
(right) Relative expression levels of wild-type and pseudoexon-containing transcripts by qRT-PCR. The ratio between the two isoforms in samples
silenced for either hnRNP F or H was also calculated. (B) Transient overexpression of hnRNP F. (left) GeneMapper windows displaying fluorescence
peaks corresponding to RT-PCR products obtained from the cDNA of cells transfected with constructs expressing the M minigene with or without
hnRNP F overexpression. The fluorescence peak areas were measured by the GeneMapper v4.0 software. The X-axis represents data points (size
standard peaks are also indicated) and the Y-axis represents fluorescence units. (right) Histograms represent the relative amount of transcripts
including or skipping the pseudoexon, as assessed by calculating the ratio of the corresponding fluorescence peak areas (setting the sum of all peaks
as 100%). Bars represent mean 6 SD of 3 independent experiments, each performed in triplicate. The results were analyzed by unpaired t-test
(*P,0.05; **P,0.01; ***P,0.001).
doi:10.1371/journal.pone.0059333.g002
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which can exert their splicing-promoting activity when one of the
above-mentioned repressing conditions is abolished. However, the
complex interactions among regulatory mechanisms controlling
pseudoexon splicing are still largely unexplored.
In this work, we made use of a mutation-activated pseudoexon
in the FGG gene, previously identified by our group, to investigate
the cis- and trans-acting factors controlling pseudoexon inclusion in
the mature transcript.
A combination of bioinformatics predictions and functional
analyses of regulatory sequences led to the identification of a 25-bp
region, whose presence is important for pseudoexon inclusion.
This region contains both an hnRNP H/F (G-run motif) and
several putative SR-protein binding sites, which were functionally
characterized by performing pulldown experiments and modulat-
ing the levels of the corresponding trans-acting interactors.
The strength and specificity of the binding of SR and hnRNP
proteins to the 25-bp region, suggested that hnRNP H/F might
represent important regulatory factors, possibly through the
interaction with a G-run element at position +13/15 of the
pseudoexon sequence. Even though these trans-acting splicing
regulators are generally regarded as splicing repressors, recent
works suggested that their role is probably much more complex.
Indeed, a large survey on the contribution of hnRNP A1 and H on
alternative splicing revealed that these proteins can stimulate both
exon inclusion and skipping events [29]. To test whether hnRNP
H and F modulate pseudoexon inclusion in the mature transcript,
both proteins were knocked down by siRNAs in HeLa cells.
Silencing of hnRNP F unexpectedly resulted in decreased
pseudoexon inclusion, indicating that, in this position, it can act
as a positive modulator of FGG pseudoexon splicing.
In addition, unlike other genes in which hnRNP H and F have
overlapping functions in vivo [18,19,30], our results suggest that
these two proteins are not completely redundant in regulating FGG
pseudoexon inclusion. Indeed, while knockdown of hnRNP F
decreases pseudoexon inclusion, silencing of hnRNP H does not
significantly alter FGG splicing, although both proteins are silenced
at similar levels (Figure 2). Partially overlapping but non-
redundant function of hnRNP H and F has also been reported
for the DM20 gene [31].
Considering that the 75-bp pseudoexon includes two additional
G-runs, i.e. a gGGGG stretch at position -1/+4 (G1) and a GGG
motif at position +60/63 (G3) (Figure 1), the specific contribution
of hnRNP F binding to the G-run motif within the 25-bp region
(G2) was analyzed by RNAi experiments in cells transfected with
the 25-bp-deleted minigene. In the absence of this region, hnRNP
F silencing led to a significant increase in pseudoexon inclusion,
confirming that the splicing-enhancing activity of hnRNP F in the
wild-type pseudoexon sequence is specifically mediated by the 25-
bp region.
Although promising, the results obtained using the 25-bp-
deleted minigene -in which the pseudoexon has been shortened to
50 bp- might be partially affected by the intrinsic tendency of
skipping of small exons [32]. To avoid this confounding effect and
to confirm the splicing-enhancing activity of the 25-bp region,
a fine mapping of specific enhancer elements was performed. In
particular, further dissection of hnRNP F binding sites within the
whole FGG pseudoexon, by multiple small deletions removing the
G-run elements, nicely confirmed that the G2 element is a splicing
enhancer, whereas the G1 and G3 motifs act as canonical ESS
(Figure 5). Moreover, a second functional purine-rich element
within the 25-bp region was found, which might cooperate with
the enhancer G2-run in hnRNP F responsiveness. Interestingly,
the two identified ESEs were functional only in HepG2 cells,
revealing a cell-type specific regulation of pseudoexon splicing.
This might be dependent, at least in part, on the difference in
hnRNP F levels between the two analyzed cell models (Figure
S4A), although the involvement of additional hepato-specific trans-
acting factors cannot be ruled out. Indeed, when hnRNP F was
overexpressed in HepG2, we obtained, for all M mutant
constructs, a response more similar to that obtained in HeLa in
basal condition (Figure S4B), suggesting that the fine regulation of
splicing factor levels in different cell lines is important to modulate
the amount of pseudoexon recognition by the splicing machinery.
Concerning the question of how the G-runs or hnRNP F increase
exon-definition, recent reports have suggested that G-stretches
near to donor sites may act co-operatively to recruit U1snRNA,
either through direct binding or through other splicing factors
[33]. This effect, however, was shown to be critically dependent on
the proximity of the G-run to the splice site. In our case,
considering the distance between the G2 element and the 59 splice
site of FGG pseudoexon, this possibility is rather unlikely.
Alternatively, we can speculate that our G-runs may also mediate
direct binding of U2AF35 to the 39 splice site of the pseudoexon,
a possibility that would be interesting to test in the future.
Taken together, these results highlight several important issues
with regards to splicing regulation. First of all, the importance of
always checking experimentally, whenever possible, the trans-
acting factors binding to in-silico predicted elements. Although in-
silico methods are constantly improving, there is still a major gap
between predicted and actual binding sites, as shown in our
pulldown experiments. A second consideration regards the
importance of not making too close a parallelism between the
presence of a specific regulator and its potential effects on the
inclusion (or exclusion) of any pre-mRNA sequence in the mature
transcript. Indeed, our data suggest that hnRNP F can act either as
activator or as repressor of pseudoexon inclusion through the
binding of different cis-acting elements.
Finally, this study highlights the intrinsic complexity of the
splicing process, even in sequences that are not subjected to
evolutionary pressure (Figure S1B).
Materials and Methods
Plasmids
The minigene construct pT-FGG-IVS6-320A.T, containing
the mutant IVS6-320A.T human FGG genomic region spanning
from intron 4 to intron 7 (based on GenBank accession number
NG_008834), was previously described [17]. The deletion mutants
(M-del25, M-del8, M-delG1, M-delG2, M-delG1G2, M-delG1G3,
M-delG2G3, M-delG1G2G3) were produced by site-directed
mutagenesis with oligonucleotides (Sigma-Aldrich, St Louis,
MO, USA; sequences available upon request) carrying the
Figure 3. In-silico prediction of an ESE-enriched 25-bp sequence and identification of the interacting proteins. (A) Schematic
representation of the minigene construct containing the 75-bp FGG pseudoexon activated by the IVS6-320A.T mutation (indicated by an arrow).
(bottom) ESE elements predicted by the ESEFinder program (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process = home) in the
pseudoexon sequence are indicated by the histogram bars; the ESE-enriched 25-bp sub-region is underlined. (B) Western blot analysis of RNA-
protein pulldown assays for the identification of trans-acting factors binding to the 25-bp region. (top) Sequences used in pulldown experiments.
(bottom) Western blot analysis of hnRNP and SR proteins immunoprecipitated from HeLa nuclear extracts with either the wild-type or the scrambled
25-bp (as negative control) pseudoexon sequence.
doi:10.1371/journal.pone.0059333.g003
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Figure 4. Functional characterization of the 25-bp region. (A) Effect of the 25-bp region on pseudoexon inclusion. Minigene constructs either
containing (M) or lacking (M-del25) the 25-bp region were transiently transfected in HeLa cells. The relative amount of pseudoexon inclusion was
measured by fluorescent RT-PCR. (top) Schematic representation of the RT-PCR products; primers used in RT-PCR experiments are indicated by
arrows. The length of each fragment is also indicated. (bottom, left and middle panels) GeneMapper windows displaying fluorescence peaks
corresponding to the RT-PCR products. The fluorescence peak areas were measured as described in Figure 2B legend. (bottom, right panel)
Histograms representing the relative amount of transcripts including or skipping the pseudoexon, as assessed by calculating the ratio of the
G-runs Regulating FGG Pseudoexon Inclusion
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nucleotide deletion. For the M-del25 mutant, the mutagenesis
reaction was carried by using a slight modification of the
QuickChange Site-Direct Mutagenesis Kit protocol (Agilent
Technologies Inc, Santa Clara, CA, USA), consisting in the use
of longer primers (50 nucleotides) bridging the deletion site. All
constructs were purified by the EndoFree Plasmid Maxi Kit
(Sigma-Aldrich) and checked by DNA sequencing using the
BigDye Terminator Cycle Sequencing Kit v1.1 and an automated
ABI-3130XL DNA sequencer (Life Technologies, Carlsbad, CA,
USA).
The plasmid pCG-SRp40 used for overexpression experiments
was previously described [34]. The pCDNA3-hnRNP F plasmid
for hnRNP F overexpression was obtained by cloning the
amplified cDNA sequence of this protein (AAH01432) in the
commercial pcDNA3 vector (Life Technologies).
Cell Culture, Transfection, and RNA Extraction
Human cervix carcinoma HeLa cells were maintained in
Dulbecco modified Eagle’s medium (EuroClone, Milan, Italy),
HepG2 cells were cultured in RPMI 1640 (EuroClone) additioned
with sodium pyruvate (1 mM; Sigma-Aldrich). Both media were
supplemented with 10% fetal bovine serum, 1% glutamine, and
antibiotics (100 U/mL penicillin and 100 mg/mL streptomycin;
EuroClone). Cells were grown at 37uC in a humidified atmosphere
of 5% CO2 and 95% air, according to standard procedures.
In each transfection experiment, an equal number of cells
(250,000) were transiently transfected in 6-well plates with the
Fugene HD reagent (Promega, Madison, WI, USA) and 4 mg of
plasmid DNA, following the manufacturer’s instructions. Twenty-
four hours after transfection, cells were washed twice with
phosphate-buffered saline and total RNA was extracted by using
the EUROzol reagent (EuroClone), according to the manufac-
turer’s instructions.
RNA Interference
For hnRNP H and F knockdown 150,000 HeLa cells were
seeded on 3.5-cm multiwell plates. After 24 hours, 5 mL
Oligofectamine (Life Technologies) were mixed with 15 mL
Opti-MEM I reduced serum medium (Life Technologies), in-
cubated at room temperature for 7 minutes and added to 2.5 mL
(25 pmol) of siRNA duplex (10 mM), which had been mixed with
175 mL Opti-MEM I. The mixture was incubated at room
temperature for 20 minutes, and then added to the cells. After 24
hours, effector and reporter constructs were transfected as
described above. Cells were grown for an additional 24 hours
followed by RNA and protein extraction. The 20-nt target
sequences in hnRNP H and F were 59-GGAAATAGCT-
GAAAAGGCT-39 and 59-GCGACCGAGAACGACATTT-39,
respectively. A pre-designed siRNA targeting luciferase (Target
Sequence: 59-CGTACGCGGAATACTTCGA-39) (EuroClone)
was used as negative control. Silencing efficiency was assessed by
Western blotting performed according to standard protocols. The
effect of siRNA treatment against hnRNP H and F on pseudoexon
inclusion was assessed by real-time RT-PCR with transcript-
specific amplicons, as further detailed.
Real-time RT-PCR
Random nonamers and ImProm-II Reverse Transcriptase
System (Promega) were used to perform first-strand complemen-
tary DNA (cDNA) synthesis starting from 1 mg of total RNA,
according to the manufacturer’s instructions. Two primer couples
were designed in order to be specific for transcripts containing or
lacking the pseudoexon; qRT-PCR reactions (20 mL) were
performed using the 2x SYBR green master mix (Roche, Basel,
Switzerland) in a Light Cycler 480 (Roche). Oligonucleotide
sequences and cycling conditions are available on request. The
percentage of pseudoexon inclusion was calculated as the ratio
between the relative quantitation of the amplicon including the
pseudoexon (normalized by the DCt method, using as reference
gene an intron-containing transcript produced by the pTargeT
vector itself) and the relative quantitation of the skipped transcript
(normalized as described for the pseudoexon-containing tran-
script). Melting-curve analysis was used to verify that a single
product had been amplified in each real-time reaction.
Fluorescent RT-PCR
To quantify splice products, an aliquot (1 mL) of the total
reverse-transcription reaction (20 mL) was used as template in
a standard RT-PCR amplification using a fluorescein-labeled
exonic forward primer (FGG–Ex5-F-FAM: 59-[6FAM]AGAAGG-
TAGCCCAGCTTGA-39) and the exonic reverse oligonucleotide
FGG–Ex7-R (59-ATTCCAGTCTTCCAGTTCCA-39). For ex-
periments in HepG2, the reverse primer was substituted with the
commercial pTargeT sequencing primer (Promega) to discrimi-
nate transcripts produced by the transfected construct from the
endogenous FGG mRNA. PCRs were carried out under standard
conditions using the FastStart Taq DNA Polymerase (Roche) on
a Mastercycler EPgradient (Eppendorf AG, Hamburg, Germany).
PCR reactions were separated on an ABI-3130XL sequencer and
the peak areas measured by the GeneMapper v4.0 software. The
level of pseudoexon inclusion was assessed by measuring the ratio
of the fluorescence peak areas corresponding to the transcript
including or skipping the pseudoexon. Because the two PCR
products are amplified by the same primers, and the two
amplicons have similar amplification efficiencies (as assessed by
generating standard curves for each amplicon using real-time
PCR, data not shown), the ratio of amplified products reflects the
relative abundance of the templates before PCR.
Pulldown Protocol
RNA probes containing the wild-type 25-bp region and
a scrambled version of the same sequence (as negative control)
were obtained by chemical synthesis from Sigma-Aldrich; as
control of the RNA precipitation an unrelated small RNA
oligonucleotide was used (wild type ATM 59-UGGCCAGGUAA-
GUGAUAUAU-39) [35]. The pulldown protocol has been
described in detail by Sevo and colleagues [36]. Briefly, 500
pmoles of the target RNA were placed in a 400-mL reaction
mixture containing 100 mM NaOAC pH 5.0 and 5 mM sodium
m-periodate (Sigma-Aldrich), incubated for 1 hour in the dark at
room temperature, ethanol precipitated, and resuspended in
100 mL of 0.1 M NaOAC, pH 5.0. To this RNA, 100 mL of
adipic acid dehydrazide agarose bead (50% slurry, Sigma-Aldrich)
equilibrated in 100 mM NaOAC pH 5.0 were added, and the mix
corresponding fluorescence peak areas (setting the sum of all peaks as 100%). Bars represent mean 6 SD of 3 independent experiments, each
performed in triplicate. (B) Knock-down experiments showing that silencing of hnRNP F in the absence of the 25-bp region significantly promotes
pseudoexon inclusion. Quantitation by qRT-PCR demonstrates that the hnRNP F splicing-enhancer activity is dependent on the integrity of the 25-bp
region. The results were analyzed by unpaired t-test (***P,0.001).
doi:10.1371/journal.pone.0059333.g004
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Figure 5. Functional dissection of G-run elements within the pseudoexon sequence. (top) The complete 75-bp-long pseudoexon
sequence and flanking splice sites; nucleotides belonging to the pseudoexon are in capital letters; the star indicates the IVS6-320A.T mutation; the
deleted sequences (shaded in gray) are indicated. (bottom) Histograms representing the relative amount of transcripts including or skipping the
pseudoexon, calculated for each deletion mutant as described in the legend of Figure 2B. Bars represent mean 6 SD of 3 independent experiments,
each performed in triplicate. The results were analyzed by unpaired t-test. Statistical significance was calculated referring to the M construct
(*P,0.05; **P,0.01; ***P,0.001).
doi:10.1371/journal.pone.0059333.g005
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was incubated for 12 hours at 4uC on a rotator. RNA beads were
then washed with 2 M NaCl and equilibrated in washing buffer
(5 mM HEPES pH 7.9, 1 mM MgCl2, 0.8 mM magnesium
acetate). The beads were then incubated on a rotator with
a protein mixture containing approximately 1 mg of HeLa cell
nuclear extract (Cil Biotech, Mons, Belgium) for 30 minutes at
room temperature in 1 mL final volume. The beads were
subsequently pelleted by centrifugation at 3000 rpm for 3 minutes
and washed 4 times with 1.5 mL of washing buffer, before
addition of sodium dodecyl sulfate (SDS) sample buffer and
loading on a 10% SDS-PAGE gel. The samples were analyzed by
Western blotting with a general antibody against SR proteins
(1H4, Zymed Laboratories, San Francisco, CA, USA) and several
home-made antibodies against hnRNP A/B and hnRNP H/F,
previously described in our studies [37].
Supporting Information
Figure S1 Analysis of FGG pseudoexon donor splice site
and overall sequence conservation. (A) Comparison of
cryptic donor splice site of the pseudoexon with all the sequences
of the physiologic donor sites in FGG exons. (B) UCSC snapshot
showing the alignment of the 75-bp FGG pseudoexon sequence in
vertebrates.
(TIF)
Figure S2 Effect of the 25-bp-region removal on pseu-
doexon inclusion by qRT-PCR. (left) Minigene constructs
either containing (M) or lacking (M-del25) the 25-bp region
transiently transfected in HeLa cells. (right) Relative expression
levels of wild-type and pseudoexon-containing transcripts, and
ratio between the two isoforms in cells expressing M and M-del25
plasmid, evaluated by qRT-PCR. Bars represent mean 6 SD of 3
independent experiments, each performed in triplicate. The results
were analyzed by unpaired t-test (**P,0.01; ***P,0.001).
(TIF)
Figure S3 Effect of SRp40 overexpression on the FGG
pseudoexon splicing in HeLa cells. RT-PCRs were
performed on cDNA of cells co-transfected with the SRp40 and
the minigene M constructs by using a FAM-labeled primer. RT-
PCR products were separated by capillary electrophoresis on
a 3130XL genetic analyzer. Histograms represent the relative
amount of transcripts including or skipping the pseudoexon, as
assessed by calculating the ratio of the corresponding fluorescence
peak areas (setting the sum of all peaks as 100%). Bars represent
mean 6 SD of 3 independent experiments, each performed in
triplicate. The results were analyzed by unpaired t-test.
(TIF)
Figure S4 Differences in hnRNP F expression might
account for cell-specific inclusion levels of FGG pseu-
doexon. (A) Western blot (left) and corresponding densitometric
analysis (middle) demonstrating the endogenous expression levels
of hnRNP F protein in both HeLa and HepG2 cells. (right)
Relative expression levels of hnRNP F mRNA by qRT-PCR in the
two cell lines. (B) Histograms representing the relative amount of
transcripts including or skipping the pseudoexon, calculated by
fluorescent RT-PCR for each deletion mutant after overexpression
of hnRNP F in HepG2 cells. Bars represent mean 6 SD of 3
independent experiments, each performed in triplicate. The results
were analyzed by unpaired t-test. Statistical significance was
calculated referring to the M construct (***P,0.001).
(TIF)
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